Work

A phase II trial of erlotinib and bevacizumab for patients with metastatic melanoma

Year: 2015

Type: article

Source: Pigment Cell & Melanoma Research

DOI: 10.1111/pcmr.12394

Authors: Tejaswi V. Mudigonda, Kenneth Wyman, David R. Spigel, Kimberly B. Dahlman, F. Anthony Greco, Igor Puzanov, Mark C. Kelley, John D. Hainsworth, Jeffrey A. Sosman, Douglas B. Johnson

Institutions: Vanderbilt University Medical Center, Sarah Cannon, Tennessee Oncology

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Bristol-Myers Squibb, Novartis, National Institutes of Health, National Cancer Institute

Awards: G1679695934, G4872119764, Vanderbilt Clinical Oncology Research Career Development Award

OpenAlex ID: W2150349343

FWCI: 0.868

Cites: 10

Cited by: 14

Related to: 10